Ray Romano to Host IMF 10th Annual Comedy Celebration & #225; Nov. 5
The IMF's annual Comedy Celebration will take place on Saturday, November 5 at the Wilshire Ebell Theatre. Actor and comedian Ray Romano returns as “Everybody's Most-Loved Host,” with featured performers Bill Burr, Jeff Garlin, Dom Irrera, Larry Miller, Kevin Nealon, JB Smoove, and Fred Willard. Proceeds from the event benefit the Peter Boyle Research Fund and support the Black Swan Research Initiative® (BSRI). Renowned actor Peter Boyle died in 2006 after a four-year battle with myeloma. In celebration of the event's 10th anniversary, the event will honor Loraine Alterman Boyle for her extraordinary work as the e...
Source: International Myeloma Foundation - October 3, 2016 Category: Hematology Source Type: news
Positive Top-Line Phase 2b STORM Results Reported, with Plans for Development Path of Selinexor for the Treatment of Multiple Myeloma
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced the initiation of the STORM study (Selinexor Treatment of Refractory Myeloma) on September 6, 2016. STORM is a multi-center, single-arm Phase 2 study of selinexor (KPT-330) in heavily-pretreated patients with quad-refractory multiple myeloma. Selinexor, the company's lead, novel, oral Selective Inhibitor of Nuclear Export / SINE ™ compound, will be evaluated in combination with low-dose dexamethasone in multiple myeloma patients whose disease was refractory to treatment with bortezomib (Velcade®), lenalidomide (Revlimid...
Source: International Myeloma Foundation - September 28, 2016 Category: Hematology Source Type: news
Positive Top-Line Phase 2b STORM Results Reported, with Plans for Development Path of Selexinor for the Treatment of Multiple Myeloma
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced the initiation of the STORM study (Selinexor Treatment of Refractory Myeloma) on September 6, 2016. STORM is a multi-center, single-arm Phase 2 study of selinexor (KPT-330) in heavily-pretreated patients with quad-refractory multiple myeloma. Selinexor, the company's lead, novel, oral Selective Inhibitor of Nuclear Export / SINE ™ compound, will be evaluated in combination with low-dose dexamethasone in multiple myeloma patients whose disease was refractory to treatment with bortezomib (Velcade®), lenalidomide (Revlimid...
Source: International Myeloma Foundation - September 28, 2016 Category: Hematology Source Type: news
Watch the replay of the "Living Well with Myeloma" Teleconference on CAR T-Cell Therapy
The next “Living Well with Myeloma” teleconference will focus on CAR T-Cell Therapy: What Myeloma Patients& Caregivers Need to Know. It takes place on Thursday, September 22, 2016 at 7 PM ET / 4 PM PT. Speakers are Dr. Rafat Abonour (Indiana Universityá Simon Cancer Center) and Dr. Edward Stadtmauer (University of Pennsylvania). CAR T cells, or chimeric antigen receptor T cells, are part of a class of cancer therapies known as immunotherapies. With CAR T-cell therapy, a patient's T cells are harvested and genetically reengineered to become better able to recognize and attack myeloma. The altered T cells are then r...
Source: International Myeloma Foundation - September 21, 2016 Category: Hematology Source Type: news
View the slides for the "Living Well with Myeloma" Teleconference on CAR T-Cell Therapy
The next “Living Well with Myeloma” teleconference will focus on CAR T-Cell Therapy: What Myeloma Patients& Caregivers Need to Know. It takes place on Thursday, September 22, 2016 at 7 PM ET / 4 PM PT. Speakers are Dr. Rafat Abonour (Indiana Universityá Simon Cancer Center) and Dr. Edward Stadtmauer (University of Pennsylvania). CAR T cells, or chimeric antigen receptor T cells, are part of a class of cancer therapies known as immunotherapies. With CAR T-cell therapy, a patient's T cells are harvested and genetically reengineered to become better able to recognize and attack myeloma. The altered T cells are then r...
Source: International Myeloma Foundation - September 21, 2016 Category: Hematology Source Type: news
Kayaker Determined to Help his Mother and Uncle Battle Multiple Myeloma Completes 600-Mile Washington to Alaska Trip
Raised More than $20,000 to Support International Myeloma Foundation Research (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - September 15, 2016 Category: Hematology Source Type: news
How Research in Iceland Will Help Myeloma Patients Everywhere
As myeloma researchers at the University of Iceland prepare to launch the exciting iStopMM project, IMF Chairman Dr. Brian Durie examines the benefits this Black Swan Research Initiative® project will generate for the rest of the world: learning, screening, and treating to achieve the best outcomes for myeloma patients everywhere. To read Dr. Durie's blog, click HERE. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - September 8, 2016 Category: Hematology Source Type: news
Tune in to the FREE "Living Well with Myeloma" Teleconference on CAR T-Cell Therapy
The next “Living Well with Myeloma” teleconference will focus on CAR T-Cell Therapy: What Myeloma Patients& Caregivers Need to Know. It takes place on Thursday, September 22, 2016 at 7 PM ET / 4 PM PT. Speakers are Dr. Rafat Abonour (Indiana Universityá Simon Cancer Center) and Dr. Edward Stadtmauer (University of Pennsylvania). CAR T cells, or chimeric antigen receptor T cells, are part of a class of cancer therapies known as immunotherapies. With CAR T-cell therapy, a patient's T cells are harvested and genetically reengineered to become better able to recognize and attack myeloma. The altered T cells are then r...
Source: International Myeloma Foundation - September 2, 2016 Category: Hematology Source Type: news
Expanding Our Knowledge About Daratumumab and More
Three important new reports are shedding light on how daratumumab works, reports IMF Chairman Dr. Brian Durie in his blog this week. “Our understanding of its benefits—when used alone and in combinations—is evolving rapidly.” But is treatment outpacing reimbursement? Also, this week, Dr. Durie touches on cancer in 9/11 responders, a study that suggests social status may affect outcomes, and a new bestseller that explores the science-fiction-sounding “microbiome.” (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - August 25, 2016 Category: Hematology Source Type: news
The Most Important Questions Facing Myeloma Experts in 2016
Close to one hundred members of the International Myeloma Working Group (IMWG) gathered in Copenhagen from June 7th to 9th, just prior to the European Hematology Association (EHA) meeting, for the seventh annual IMWG Summit. This important and prestigious meeting allows myeloma experts from around the globe to discuss pressing issues and to set an agenda of publications, clinical trials, and advocacy efforts for the coming year. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - August 17, 2016 Category: Hematology Source Type: news
Myeloma Experts of the IMWG Tackle Soaring Costs of Care
Recognizing our responsibility to lead the way in addressing costs effectively, members of the International Myeloma Working Group (IMWG), the research arm of the IMF, launched a plan of action at a special session of the June 2016 annual meeting held in Copenhagen this year. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - August 16, 2016 Category: Hematology Source Type: news
Takeda Receives Marketing Authorization in Canada for NINLARO ™ (ixazomib) in Relapsed/Refractory Multiple Myeloma
NINLARO™ is the first and only oral proteasome inhibitor approved to provide a new treatment option for adult patients living with multiple myeloma in Canada who have received at least one prior therapy (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - August 8, 2016 Category: Hematology Source Type: news
NLB New Publications and Resources
Scroll down to learn more. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - August 4, 2016 Category: Hematology Source Type: news
The IMF's International Myeloma Working Group Establishes Updated Yardstick for Disease Assessment in the Evolving Treatment Landscape of 2016
< p align="center" > & nbsp; < em > New Categories of Minimal Residual Disease (MRD) Negativity < /em > < /p > < p align="center" > < em > & nbsp;Provide Clinical Trial Endpoints and Framework for Cure < /em > < /p > (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - July 27, 2016 Category: Hematology Source Type: news
